NASH drug in hand, Merck forges ahead with 2-year extension of NGM Bio collaboration deal
The past four years of collaborating with NGM Bio has delivered a late-stage NASH drug for Merck, which paid up $20 million to license the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
